The brokerage retained its underperform rating and Rs 326 target price, saying the recent block deal does not materially ...

Mylan, part of Viatris, exits Biocon by selling its 5.64% stake for ₹3,679 crore. Domestic mutual funds and global investors ...

According to Business Today sources, the floor price has been set at Rs 378.50 per share, a 7.9 per cent discount to Biocon's ...

ICICI Prudential Mutual Fund was the largest buyer among 36 investors, picking up 3.68 crore equity shares (2.26 percent ...

By Yantoultra Ngui SINGAPORE, July 13 (Reuters) - Mylan Inc, part of a global healthcare company Viatris, plans to sell up to 92 million shares in Indian drugmaker Biocon Ltd, worth up to 34.81 ...

As many as 9.2 crore shares, representing a 5.64 percent stake in Biocon, changed hands in the pre-open block deal window at ...

The Viatris arm looks to offload 92 million equity shares, marking a financial exit following a series of biosimilar asset ...

Biocon Ltd shares jumped sharply on Tuesday following a huge block deal worth Rs. 3,676, triggering strong buying in the biotechnology stock. Nearly 9.19 crore ...

Mylan, part of global healthcare company Viatris, plans to sell up to 92 million shares in Biocon through a secondary ...

New Delhi, Jul 14 (PTI) Mylan Inc, a part of global healthcare company Viatris, on Tuesday exited Biocon Ltd by selling its ...

Viatris-owned Mylan looks to sell its entire 5.64% stake in Biocon through a block deal at a floor price of ₹378.50 per share ...